Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Efficacy of ERN/LRPT in Dyslipidemia
NCT00961636Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of laropiprant in dyslipidemia, sponsored by Merck & Co.. Started Oct 2009; status: completed.
02
Drugs
laropiprant
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT00961636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00961636.